Business Overview: Vaso Corporation (OTC: VASO)

---

Executive Summary

Vaso Corporation is a diversified healthcare equipment and technology holding company operating through three distinct businesses: a healthcare IT/managed-network services arm, a medical equipment sales-representation business, and a proprietary cardiovascular device and software manufacturer. Incorporated in Delaware in July 1987 and headquartered in Plainview, New York, the company has evolved considerably from its original cardiovascular-therapy roots (dating to 1995) through a series of acquisitions and a 2016 rename from Vasomedical to Vaso Corporation.

The three businesses sit under one roof but serve fundamentally different markets: VasoTechnology sells managed IT and network services to healthcare facilities, VasoHealthcare is the exclusive sales representation arm for GE HealthCare's diagnostic imaging equipment to the U.S. "middle market," and VasoMedical designs and sells proprietary cardiovascular monitoring devices in the U.S. and China.

---

1. Core Business Model & How They Work

[ GEHC Exclusive Sales Rep ] + [ Managed IT/Network Services ] + [ Proprietary Device Sales ] ➡️ [ Diversified Revenue Across 3 Healthcare Niches ]

Key Operational Drivers

1. Exclusive Agency Model (VasoHealthcare): Rather than manufacturing imaging equipment itself, Vaso earns commission revenue as the exclusive sales representative for GE HealthCare diagnostic imaging and ultrasound equipment, service agreements, training, and financing — a capital-light way to participate in a market dominated by giants.
2. Sticky, Recurring IT Contracts (VasoTechnology): Through its NetWolves subsidiary (acquired May 2015), the company provides managed network transport as an FCC-licensed carrier reselling to more than 175 healthcare facility partners, plus managed healthcare software and security — a recurring-revenue business built on long-term facility relationships.
3. Proprietary Device Manufacturing (VasoMedical): The legacy business designs, manufactures, and sells cardiovascular devices — Biox Holter monitors and ambulatory blood pressure recorders, the ARCS analysis software (including a SaaS subscription), the MobiCare vital-sign monitoring system, and EECP therapy systems — sold directly in the U.S. and China and through distributors internationally.
4. Portfolio Rationalization: The company has actively reshaped its portfolio over time: selling 51% of its EECP Global business to PSK in 2020, and terminating a proposed Achari business combination agreement in September 2024, signaling an ongoing process of testing and walking away from strategic alternatives.

---

2. Business Segments

┌─────────────────────────────────┐
│          Vaso Corporation          │
└────────────────┬────────────────────┘
                  │
   ┌──────────────┼───────────────┬──────────────────┐
   ▼                ▼               ▼
┌──────────┐  ┌───────────────┐  ┌──────────────┐
│    IT      │  │  Professional  │  │  Equipment    │
│(VasoTech-  │  │  Sales Service  │  │ (VasoMedical) │
│ nology)    │  │ (VasoHealthcare)│  │               │
│ ~49% of    │  │  ~48% of        │  │  ~3% of        │
│ 2024 revenue│  │  2024 revenue   │  │  2024 revenue  │
└──────────┘  └───────────────┘  └──────────────┘

1. IT (VasoTechnology) — ~$42.95M of 2024 revenue

Managed healthcare software, network infrastructure, and managed network transport/security sold to hospitals and healthcare facilities, including as an FCC-licensed carrier.

2. Professional Sales Service (VasoHealthcare) — ~$41.3M of 2024 commission revenue

An 70-to-80-person sales force exclusively representing GE HealthCare diagnostic imaging and ultrasound equipment, plus related service agreements, training, and financing, to U.S. middle-market healthcare providers.

3. Equipment (VasoMedical) — ~$2.5M of 2024 revenue

Proprietary cardiovascular devices and software (Biox, ARCS, MobiCare, EECP) sold directly in the U.S. and China and through international distributors; the smallest and most mature segment, down 12.5% year over year.

---

3. Product Portfolio

---

4. Competitive Landscape

Vaso's three businesses face entirely different competitive sets:

• Diagnostic imaging (VasoHealthcare): Competes against Siemens, Philips, Canon, and Hologic, and their own channel partners — with GE HealthCare itself described as a leading competitor in the broader market even as Vaso sells on its behalf in a defined middle-market channel.
• Healthcare IT VAR (VasoTechnology): Competes with Agfa Healthcare, McKesson, Philips, and Carestream Health.
• Managed network services (VasoTechnology): Competes with telecom giants Verizon, AT&T, and CenturyLink, as well as IBM, Cisco resellers, Siemens, Epic, regional IT integrators, and healthcare facilities' own internal IT departments.
• Ambulatory monitoring (VasoMedical): Faces numerous competitors of varying size, though Vaso notes Biox is among the few Chinese-made products holding simultaneous CE, CFDA, FDA, and ANVISA qualifications — a genuine, if narrow, regulatory differentiator.

   VASO'S THREE-BUSINESS COMPETITIVE MAP
┌──────────────────────────────────────────────────────┐
│  IT Segment:        [Verizon/AT&T] vs [VasoTechnology] │
│                      (Scale giants vs. niche reseller)  │
│                                                          │
│  Sales Segment:     [Siemens/Philips] vs [VasoHealthcare]│
│                      (OEMs vs. exclusive GEHC agent)     │
│                                                          │
│  Equipment Segment: [Many small players] vs [VasoMedical]│
│                      (Fragmented niche, regulatory moat)  │
└──────────────────────────────────────────────────────┘

---

5. Strategic Strengths & Risks

Competitive Strengths (The Moat)

• Exclusive GEHC Sales Agency: The VasoHealthcare arrangement gives Vaso access to GE HealthCare's product strength and brand in the U.S. middle market without the capital intensity of manufacturing imaging equipment.
• Sticky Network Carrier Relationships: 175+ facility partners relying on Vaso's FCC-licensed managed network transport represent a recurring, switching-cost-protected revenue base.
• Multi-Jurisdiction Regulatory Approvals: Biox's simultaneous CE, CFDA, FDA, and ANVISA qualifications are a genuine, non-trivial regulatory barrier that smaller competitors in ambulatory monitoring may lack.

Strategic Risks & Vulnerabilities

1. Dependence on a Single OEM Relationship: VasoHealthcare's entire professional sales segment rests on its exclusive representation agreement with GE HealthCare — a relationship Vaso does not control and that could change terms or end.
2. Scale Disadvantage Across All Three Businesses: Vaso is a small player competing against Siemens, Philips, Verizon, AT&T, and other vastly larger rivals in every one of its three markets.
3. Declining Legacy Equipment Business: The VasoMedical segment fell 12.5% year over year in 2024, suggesting the original cardiovascular device business is in secular decline even as the other two segments grow.
4. Strategic Uncertainty: The September 2024 termination of the proposed Achari business combination highlights an unresolved strategic direction and a history of exploring, then abandoning, major structural alternatives.

---

6. Financial Overview

---

7. Summary Conclusion

Vaso Corporation is a small, diversified healthcare holding company whose real competitive advantage lies in two specific, durable relationships: its exclusive sales representation of GE HealthCare equipment and its position as an established, FCC-licensed network carrier to more than 175 healthcare facilities. Its legacy cardiovascular device business, while differentiated by a genuine multi-jurisdiction regulatory moat, is shrinking and now a minor part of overall revenue. The company's path forward depends on continuing to grow the IT and professional-sales agency businesses while managing its dependence on partners — GE HealthCare chief among them — whose strategic decisions it cannot control.